The company is paying China-based biotech LaNova Medicines $588 million for the kind of dual-pronged antibody drug that ...

In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

UCSF researchers develop customizable SNIPR sensors that activate engineered cells only near tumors, promising precise cancer ...

The company will still have some catching up to do, as LM-299 is early in clinical development, with a phase 1 trial ...

Advertisement Specific types of immune cells unleashed by cancer immunotherapy appear to cause myocarditis, an inflammatory ...

TIL-Tregs specifically increase GLUT3 expression for glucose uptake in tumors. - GLUT3 fuels protein O-GlcNAcylation, ...

The immune system is a major target for cancer treatments. Immune checkpoint inhibitors and CAR-T cell therapy can ...

Some patients being treated with immune checkpoint inhibitors, a type of cancer immunotherapy, develop a dangerous form of heart inflammation called myocarditis. Researchers have now uncovered the ...

Dr. Watanabe and his team from Niigata University have revealed that PET/CT image analysis using artificial intelligence (AI) ...

Researchers at the Icahn School of Medicine at Mount Sinai have discovered a way that ovarian cancer tumors manipulate their ...

The process of identifying promising small molecule drug candidates that target cancer checkpoints may become faster and smarter through virtual screening, according to Weill Cornell Medicine ...

Immunotherapy has dramatically improved the treatment outcomes of primary lung cancer; however, it sometimes causes a serious ...